2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Mucositis
4
Hematologic Neoplasms
3
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Thrombocytopenia
1
Sarcoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neutropenia
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphopenia
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Graft vs Host Disease
1
Cytopenia
1
Chondrosarcoma
1
Bone Neoplasms
1
Anemia
1
Interventions
Cyclophosphamide
62
fludarabine phosphate
55
Peripheral Blood Stem Cell Transplantation
44
ruxolitinib
41
Tacrolimus
41
Busulfan
40
Mycophenolic Acid
36
Whole-Body Irradiation
32
Antilymphocyte Serum
29
Methotrexate
27
Cyclosporine
27
fludarabine
24
Melphalan
19
Filgrastim
19
Radiotherapy
15
Methylprednisolone
13
thymoglobulin
12
Stem Cell Transplantation
12
Etoposide
12
Cord Blood Stem Cell Transplantation
12
Azacitidine
12
Sirolimus
11
Flow Cytometry
10
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
10
Psychiatric Rehabilitation
9
Decitabine
9
Specimen Handling
8
Prednisone
8
Cytarabine
8
navitoclax
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Primary Myelofibrosis
×
angiotensin I (1-7)
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled